A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
Clinical trial NCT03616964 · COMPLETED
Trial details
- NCT number
- NCT03616964
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-02
- Primary completion
- 2021-09-24
- Enrollment
- 778
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.